Induction of the remission by use of infliximab in RA
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000003344
- Lead Sponsor
- Division of Rheumatology, Department of Internal Medicine, Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who correspond to the contraindication for use of infliximab and MTX 2) Patients who are more than 70 years old at enrollment 3) Patients who have contracted RA for more than 10 years 4) Patients who are treated with more than 10mg of predonisolone 5) Other patients whom the investigator considers to be unsuitable for the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of patients who maintain their DAS28-ESR score less than 3.2 one year after discontinuance of infliximb
- Secondary Outcome Measures
Name Time Method